Latest news with #VertexPharmaceuticalsInc.
Mint
05-08-2025
- Business
- Mint
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut
Wall Street Today: The US benchmark indices, the Dow Jones, Nasdaq, and S&P 500, open higher as investors focus on optimism over a potential US Fed rate cut and corporate earnings in the US markets. Investors are focusing their attention on an upcoming interest rate cut from the US Federal Reserve (Fed) on the backdrop of last week's US job data release. According to the US Bureau of Labour Statistics' latest data release, the total US nonfarm payroll employment data witnessed an addition of 73,000 jobs in July 2025. 'Employment continued to trend up in health care and in social assistance. Federal government continued to lose jobs,' according to the US jobs data release. At 9:30 a.m. (EDT), The Dow Jones Industrial Average rose 0.06% at the opening bell at 44,200.07 points, compared to 44,173.64 points at the previous US market close. Companies like Amazon Inc., Caterpillar Inc., Travelers Cos. Inc., 3M Co., Boeing Co., UnitedHealth Group Inc., Walmart Inc., American Express Co., Home Depot Inc., CiscoSystemsInc., Goldman Sachs Group Inc., Procter & GambleCo., Nike Inc., Merck & Co. Inc., Coca-Cola Co., Johnson & Johnson, NVIDIA Corp., JPMorgan Chase & Co., Honeywell International Inc., Verizon Communications Inc., Microsoft Corp., Sherwin-Williams Co. were among the gainers for the day. Other firms, such as International Business Machines Corp., Chevron Corp., Salesforce Inc., Walt Disney Co., McDonald's Corp., Apple Inc., Amgen Inc., and Visa Inc., were among the losers for the day. The S&P 500 index also opened 0.11% higher at 6,336.63 points, compared to 6,329.94 points at the previous stock market close. Companies like Axon Enterprise Inc., Palantir Technologies Inc., Leidos Holdings Inc., Intel Corp., Cummins Inc., Pfizer Inc., Broadridge Financial Solutions Inc., Archer Daniels Midland Co., Duke Energy Corp., and CarMaxInc. were among the gainers on Tuesday. Gartner Inc., Vertex Pharmaceuticals Inc., TransDigm Group Inc., Henry Schein Inc., Zebra Technologies Corp., Fidelity National Information Services Inc., Eaton Corp., ONEOK Inc., Diamondback Energy Inc., and BallCorp. were among the laggards of the day. The Nasdaq Composite index opened 0.18% higher at 21,092.097 points, compared to 21,053.58 points at the previous Wall Street close. Stocks like CaliberCos Inc., Solarmax Technology Inc., Y-mAbs Therapeutics Inc., Staar Surgical Co., Adaptimmune Therapeutics PLC ADR, Xometry Inc., A Ontrak Inc., Castle Biosciences Inc., Arteris Inc., and Origin Materials Inc. were among the gainers. Ichor Holdings Ltd, SMX (Security Matters) PLC, AYRO Inc., Nuwellis Inc., Snail Inc., Safe & Green Holdings Corp., zSpace Inc., Bollinger Innovations Inc., Vertex Pharmaceuticals Inc., and Lichen International Inc. were among the losers. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Yahoo
30-01-2025
- Health
- Yahoo
NHS Rolls Out £1.7 Million Gene Therapy for Sickle Cell Disease
(Bloomberg) -- One of the world's most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service. Manhattan's Morning Commute Time Drops With New Congestion Toll Trump Paves the Way to Deputize Local Police on Immigration Housing Aid Uncertain After Trump's Spending Freeze Memo Trump's Federal Funding Pause Threatens State Financials How the 2025 Catholic Jubilee Is Reshaping Rome The one-time gene-editing therapy Casgevy, developed by Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG, has a list price of £1.7 million ($2.1 million), but England's drug cost regulator said it has negotiated a lower, undisclosed price. About 1,700 people could be eligible for the therapy, which aims to repair genetic code, although it's likely only about 50 patients a year will receive it given the complexity of the treatment. Sickle cell disease affects the red blood cells and causes extreme pain, organ damage and can shorten a patient's life. Only some patients with the disease will be eligible to receive Casgevy. The treatment is designed to work by editing the faulty gene in a patient's bone marrow stem cells. The cells are taken out of the bone marrow, edited in a laboratory and infused back into the patient — after which the results have the potential to be life-long. Since it's discovery more than a decade ago, Crispr technology has been expected to bring about a revolution in medicine. The decision announced Friday reverses an earlier rejection in draft guidance from the regulator. The treatment will be rolled out under a so-called managed access program, where more data is collected to help the regulator — the National Institute for Health and Care Excellence — understand the longer-term benefits before it re-assesses the drug. England has a stringent process to assess the cost-effectiveness of new medicines, and NICE decides which drugs will be available free to patients on the NHS. With the health service under growing financial pressure, the regulator has faced recent criticism over its refusal to accept some cancer medicines. Still, the UK was the first country to approve Casgevy in 2023 and the treatment is already available to a smaller group of patients with a serious form of beta-thalassemia, a hereditary blood disorder that requires repeated transfusions. The treatment for sickle cell requires chemotherapy, meaning it's likely only patients with the most severe and progressive problems will benefit, said David Rees, professor of pediatric sickle cell disease at King's College London. Despite his concerns, he said it 'offers a really important new treatment option.' 'Excitingly, advances in gene editing are happening very rapidly at the moment and it seems likely that cheaper, safer and more effective forms of gene editing will emerge for sickle cell disease over the coming years,' he said. Indy Pass, the Anti-Vail Seasonal Ski Ticket, Is Gaining Fans The Internet Almost Killed Barnes & Noble, Then Saved It What America's Tech Billionaires Really Bought When They Backed Donald Trump Musk Pitches New Narrative as Tesla Sales Fall Forget Factories, Small US Towns Want Buc-ee's Gas Stations ©2025 Bloomberg L.P.
Bloomberg
30-01-2025
- Health
- Bloomberg
NHS Rolls Out £1.7 Million Gene Therapy for Sickle Cell Disease
One of the world's most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service. The one-time gene-editing therapy Casgevy, developed by Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG, has a list price of £1.7 million ($2.1 million), but England's drug cost regulator said it has negotiated a lower, undisclosed price.
